To assess the level of preparedness of EU/EEA Member States to respond to zoonotic avian flu outbreaks, ECDC has carried out two surveys - one assessing the laboratory capacity for molecular diagnosis and characterisation of zoonotic influenza viruses, and the other focusing on measures applied to protect exposed people during outbreaks of highly pathogenic avian influenza.
In a technical report published today, ECDC, proposes a targeted testing approach in areas with ongoing avian influenza outbreaks in poultry and detections in wild birds and other animals, focusing on severe respiratory or unexplained neurological disease.
At the start of European Immunization Week, the ECDC report “Poliomyelitis situation update” reveals that between 2012 and 2021, approximately 2.4 million children in the EU/EEA may have not received three doses of polio-containing vaccines on time. Additionally, the newly published ECDC “Measles Annual Epidemiological Report 2022” highlights the risks when having pockets of an under-vaccinated population or groups not immunised at all.
The situation regarding avian influenza continues to evolve in Europe and globally, with reports of new outbreaks in birds and occasional infections in mammals. Sporadic human infections have been reported in countries outside the EU, while the risk to the public in the EU remains low.
In February 2023, Cambodia reported a family cluster in Sithor Kandal district, Prey Veng province, with two people (a girl and her father) infected with avian influenza A(H5N1) virus.
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.
Globally, as of 9 August, 19 cases of polio due to wild poliovirus type 1 (WPV1) and 223 cases due to circulating vaccine derived poliovirus (cVDPV) have been reported this year. In 2022, the cVDPV cases have been reported in 15 countries, with 93% of the cases attributed to cVDPV type 2 (cVDPV2).